Skin disorder therapeutic - Derm-Biome Pharmaceuticals
Latest Information Update: 01 Dec 2023
At a glance
- Originator Derm-Biome Pharmaceuticals
- Class Antineoplastics; Skin disorder therapies
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Actinic keratosis; Squamous cell cancer
Most Recent Events
- 28 Nov 2023 Derm-Bio Pharma enters into a collaboration agreement with Massacheusetts General hospital for the development of the topical skin disorder therapeutic
- 28 Nov 2023 Preclinical trials in Squamous cell cancer in USA (Topical)
- 28 Nov 2023 Preliminary pharmacodynamic data from the preclinical studies in squamous cell carcinoma released by Derm-Biome Pharma (Prior to November 2023)